Literature DB >> 31169437

A novel prognostic score model based on combining systemic and hepatic inflammation markers in the prognosis of HBV-associated hepatocellular carcinoma patients.

Tingting Zhang1, Zhe Liu2, Xiangqian Zhao2, Zhiyuan Mao3, Li Bai4.   

Abstract

Objectives: The study aimed to evaluate the prognostic value of systemic inflammation markers [neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), Prognostic Nutritional Index (PNI)] and hepatic inflammation markers [aspartate aminotransferase-to-platelet ratio index (APRI), γ-glutamyl transferase (γ-GT)/alanine aminotransferase (ALT)] in patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and further to develop a novel prognostic score model.
Methods: A total of 401 cases with HBV-associated HCC who underwent hepatectomy as initial therapy were included in the analysis. Kaplan-Meier was performed to construct survival curves and receiver operating characteristic (ROC) analysis was used to detect the optimal cut-off value of markers. The prognostic score model was constructed using significant inflammation markers in the Cox model. Each factor was given a score of 1 and patients were stratified according to the scores.
Results: In the Cox model, α-fetoprotein (AFP), ALT, tumour differentiation, maximum size of tumours, TNM stage, PNI and γ-GT/ALT were independently prognostic factors. We established a preoperative inflammation-based prognostic scoring model combining PNI and γ-GT/ALT. The novel preoperative inflammation-based prognostic score was superior (area under the curve [AUC], 0.659) to 7th tumour-node-metastasis (TNM) stage (AUC, 0.600) despite no statistical significance (p = .1036).
Conclusion: PNI and γ-GT/ALT are independent predictors for prognosis. The novel prognostic score model based on systemic and hepatic inflammation markers is suitable for the prognosis evaluation in patients with HBV-associated HCC.

Entities:  

Keywords:  Hepatocellular carcinoma; hepatectomy; hepatitis B virus; inflammation; prognosis

Mesh:

Substances:

Year:  2019        PMID: 31169437     DOI: 10.1080/21691401.2019.1573174

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  5 in total

1.  Preoperative application of systemic inflammatory biomarkers combined with MR imaging features in predicting microvascular invasion of hepatocellular carcinoma.

Authors:  Xun Xu; Shuwen Sun; Qiuping Liu; Xisheng Liu; Feiyun Wu; Chong Shen
Journal:  Abdom Radiol (NY)       Date:  2022-03-10

2.  Prognostic Significance of Platelet-to-Lymphocyte Ratio (PLR) in Extrahepatic Metastasis of Hepatocellular Carcinoma After Curative Resection.

Authors:  Yifan Chen; Jianxing Zeng; Pengfei Guo; Jinhua Zeng; Jingfeng Liu
Journal:  Cancer Manag Res       Date:  2021-02-12       Impact factor: 3.989

3.  A nomogram based on combining systemic and hepatic inflammation markers for predicting microscopic bile duct tumour thrombus in hepatocellular carcinoma.

Authors:  Jun-Yi Wu; Ju-Xian Sun; Jia-Yi Wu; Xiao-Xiao Huang; Yan-Nan Bai; Yong-Yi Zeng; Zhi-Bo Zhang; Shu-Qun Cheng; Mao-Lin Yan
Journal:  BMC Cancer       Date:  2021-03-12       Impact factor: 4.430

4.  Prognostic value of combined inflammatory and nutritional biomarkers in HCC within the Milan criteria after hepatectomy.

Authors:  Hanxin Feng; Feng Xu; Yang Zhao; Tianqiang Jin; Jianbo Liu; Rui Li; Tianyi Zhou; Chaoliu Dai
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738

5.  Establishment and verification of a prognostic model of liver cancer by RNA-binding proteins based on the TCGA database.

Authors:  Anwaier Apizi; Lin Wang; Laibijiang Wusiman; Erchu Song; Yipeng Han; Tengfei Jia; Wenbin Zhang
Journal:  Transl Cancer Res       Date:  2022-07       Impact factor: 0.496

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.